Disease-free interval in metastatic breast cancer patients undergoing complete remission: implications of cross-sectional study design and biologic considerations about disease history

Breast Cancer. 2017 May;24(3):491-492. doi: 10.1007/s12282-017-0766-z. Epub 2017 Mar 6.

Authors

Giulia Galli¹, Anna Tessari², Serena Di Cosimo³

Affiliations

¹ Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian 1, 20133, Milan, Italy. giulia.galli@istitutotumori.mi.it.
² Department of Cancer Biology and Genetics, The Ohio State University, 460 West 12th avenue, Columbus, OH, USA.
³ Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian 1, 20133, Milan, Italy.

PMID: 28265812
DOI: 10.1007/s12282-017-0766-z

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Biological Products
Breast Neoplasms*
Cross-Sectional Studies
Humans
Neoplasm Metastasis
Remission Induction*

Substances

Biological Products